Clinical Trial Update: A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluates the efficacy and safety of risankizumab in participants with ulcerative colitis. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Ulcerative Colitis (UC) | Phase 3 | Status: ACTIVE_NOT_RECRUITING